Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
+$0.50 today
- Market cap
- $1.72B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
Volume 0.47M
Average 1.11M
Returns on capital
Agios Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.6%
avg -27.4%
ROIC
-38.2%
avg -40.3%
ROA
-31.8%
avg -15.7%
Analysis
ROA is currently the strongest return metric at -31.8% versus its period average of -15.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Brian Goff | Chief Executive Officer & Director | USD 1.45M | 57 | 39.00K | 0.07% |
Krishnan Viswanadhan | Chief Strategy & Operations Officer | USD 931.51K | 47 | 3.00K | <0.01% |
Sarah Gheuens | Chief Medical Officer and Head of Research & Development | USD 887.23K | 46 | 16.27K | 0.03% |
Cecilia Jones | Chief Financial Officer | USD 791.84K | 51 | 3.00K | <0.01% |
James William Burns | Chief Legal Officer | USD 780.51K | 48 | 3.00K | <0.01% |
Craig Thompson | Co-Founder | USD 50K | 73 | — | — |
Lewis Clayton Cantley | Co-Founder | USD 50K | 77 | — | — |
Shin-San Su | Co-Founder | USD 50K | 70 | — | — |
Tak Wah Mak FRSC | Co-Founder | USD 50K | 80 | — | — |
T. J. Washburn | Vice President, Controller & Principal Accounting Officer | — | 44 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 26, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
40
$4.86M
Net Transaction Value
−$4.86M
Net selling
Most Active
Gheuens Sarah
10 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 26, 26Oct 26, 2026 | Gheuens Sarah Direct | Sell | $296.5K$296,469.54 |
| Oct 22, 26Oct 22, 2026 | Gheuens Sarah Direct | Sell | $18.8K$18,760.00 |
| Oct 21, 26Oct 21, 2026 | Gheuens Sarah Direct | Sell | $55.9K$55,882.17 |
| Aug 4, 26Aug 4, 2026 | Gheuens Sarah Direct | Sell | $914.4K$914,400.00 |
| Jul 1, 26Jul 1, 2026 | Gheuens Sarah Direct | Sell | $150.5K$150,502.92 |
| Apr 2, 26Apr 2, 2026 | Burns James William Direct | Sell | $113.8K$113,848.80 |
| Apr 2, 26Apr 2, 2026 | Gheuens Sarah Direct | Sell | $102K$102,047.40 |
| Apr 2, 26Apr 2, 2026 | Jones Cecilia Direct | Sell | $109K$109,024.11 |
| Apr 2, 26Apr 2, 2026 | Milanova Tsveta Direct | Sell | $113.2K$113,224.02 |
| Apr 2, 26Apr 2, 2026 | Viswanadhan Krishnan Direct | Sell | $102.7K$102,706.89 |
1–10 of 40
Summary
Insiders reported 0 buys worth $0.00 and 40 sells worth $4.86M over the last 12 months. That adds up to net selling of $4.86M. Gheuens Sarah was the most active insider with 10 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +56.0% | +72.2% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +56.0% over three years. Forward estimates point to Revenue at +72.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Agios Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about AGIO's management, answered from reported figures.
Who manages AGIO?
Agios Pharmaceuticals, Inc. (AGIO) lists 10 active executives. The top listed executive is T. J. Washburn, Vice President, Controller & Principal Accounting Officer.
Are AGIO insiders buying or selling?
Recent insider activity shows net buying of $12.57M.
Continue the stock analysis
Jump to another research area for this company.